ALSO NOTED: BMS to pay $515M in kickback case; Sanofi gets additional Taxotere indication; and much more...

> Bristol-Myers Squibb now has the dubious distinction of the third-largest court settlement between a drug maker and the U.S. Attorney's office in Massachusetts. The drug maker agreed to pay $515 million to settle kickback claims. Report

> According to a new Frost & Sullivan report, Asia continues to draw the attention of biotech and pharma companies looking to conduct low cost trials. India, China, Australia, Hong Kong, and Taiwan are among the leading Asian countries for clinical trial work. Release

> The FDA has approved Sanofi-Aventis' Taxotere in combination with cisplatin and 5-fluorouracil for induction therapy of locally advanced squamous cell carcinoma of the head and neck before patients undergo chemoradiotherapy and surgery. Release

> The FDA has approved Amylin Pharmaceuticals' pre-filled pen-injector devices for its diabetes treatment Symlin. However, the FDA rejected the use of Amylin's SYMLIN without mealtime insulin. Release

> Daiichi Sankyo is tooting its own horn, noting that the company continues to grow as other larger pharmas downsize. Release

> Some FDA staffers can breathe a sigh of relief: Their jobs won't be farmed out to the private sector, the agency says. Report

And Finally... A rapidly spreading bacterium that is resistant to common antibiotics is worrying doctors in Sweden. Report

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.